| 王 云,蒋 雪,王 莹.盐酸埃克替尼治疗45例晚期非小细胞肺癌的临床疗效分析[J].肿瘤学杂志,2016,22(3):176-179. |
| 盐酸埃克替尼治疗45例晚期非小细胞肺癌的临床疗效分析 |
| Clinical Efficacy of Icotinib Hydrochloride for 45 Cases with Advanced Non-small Cell Lung Cancer |
| 投稿时间：2015-12-17 |
| DOI：10.11735/j.issn.1671-170X.2016.03.B004 |
|
 |
| 中文关键词: 非小细胞肺癌 盐酸埃克替尼 靶向治疗 |
| 英文关键词:non-small cell lung cancer(NSCLC) icotinib hydrochloride targeted therapy |
| 基金项目: |
|
| 摘要点击次数: 2283 |
| 全文下载次数: 750 |
| 中文摘要: |
| 摘 要：［目的］ 探讨盐酸埃克替尼治疗晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应。［方法］ 回顾性分析45例经病理学确诊的晚期NSCLC患者临床资料及埃克替尼治疗的临床疗效和不良反应。所有患者均口服盐酸埃克替尼片，125mg/次，3次/d，直至病情进展或出现不能耐受的不良反应。［结果］ 45例患者治疗1个周期后，完全缓解（CR）0例，部分缓解（PR）20例（44.4%），疾病稳定（SD）15例（33.3%），疾病进展（PD）10例（22.2%），客观有效率（ORR）为44.4%（20/45），疾病控制率（DCR）为77.8%（35/45），中位无进展生存期（mPFS）为6.3个月（95%CI：3.6~9.0），中位总生存期（mOS）为15.2个月（95%CI：11.3~19.0）。治疗相关不良反应主要为皮疹4例（8.9%），腹泻及胃部不适2例（4.4%），肝功能损害2例（4.4%）。盐酸埃克替尼治疗的疗效与吸烟史有关(P<0.05)。 ［结论］ 盐酸埃克替尼治疗晚期NSCLC疗效肯定，具有毒性低、安全性高、耐受性好的特点，作为新的表皮生长因子受体—酪氨酸激酶抑制剂，为晚期NSCLC患者的治疗提供了新选择。 |
| 英文摘要: |
| Abstract：［Purpose］ To investigate the efficacy and toxicities of icotinib hydrochloride in the treatment of patients with advanced non-small cell lung cancer(NSCLC).［Methods］ The clinical data，efficacy and toxicities of icotinib hydrochloride in the treatment of 45 cases with advanced NSClC were analyzed retrospectively．Patients were treated with icotinib hydrochloride (125mg，3 times a day) untill disease progression or intolerance with toxicities.［Results］ After one period of treatment，zero cases showed compelet response(CR)；20 cases (44．4％)showed partial response(PR)；15 cases(33.3%) achieved stable disease (SD)；and 10 cases(22．2％)had progressive disease(PD)．The objective response rate(ORR) was 44．4％(20/45)，and disease control rate(DCR) was 77．8％(35/45)．The media progression free survival(mPFS) was 6.3 months，and the media overall survival(mOS) was 15.2 months. The major toxicities were skin rash(4 cases，8.9%)，diarrhea and stomach upset(2 cases，4.4%)．Two patients had liver damage(4.4%).The efficacy of icotinib hydrochloride was associated with the smoking history (P<0．05)．［Conclusion］ Icotinib hydrochioride is effective in the treatment for advanced NSCLC，with low toxicity，good safety and tolerability. As a new epidermal growth Factor receptor-tyrosine kinase inhibitor(EGFR-TKI)，it provides a new choice for patients with advanced NSCLC. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |